Researchers home in on what is wearing out T cells

Share this content:

Sometimes even cells get tired. When the T cells of the immune system are forced to deal with cancer or a chronic infection such as HIV or hepatitis C over time, they can develop T cell exhaustion and become less effective and lose their ability to attack and destroy the invaders of the body.

While the PD-1 protein pathway has long been implicated as a primary player in T cell exhaustion, a major question has been whether PD-1 actually directly causes exhaustion. A new study seems, at least partially, to let PD-1 off the hook. It was published in the Journal of Experimental Medicine (2015; doi:10.1084/jem.20142237).

In short-term infections such as a cold or flu, PD-1 helps to regulate an initial strong T cell response, preventing the T cells from over proliferating and attacking the body's own cells after the infection is cleared. But in patients with cancer or chronic infections, blocking PD-1 has proved a highly successful therapeutic strategy that allows the T cells to fight on.

“Blocking this pathway reverses T cell exhaustion and improves tumor immunity in humans and antiviral and antitumor responses in animal models,” said corresponding author E. John Wherry, PhD, a professor of microbiology and director of the Institute for Immunology in the Perelman School of Medicine at the University of Pennsylvania. “But a key question has been whether this PD-1 pathway causes exhaustion. Our work shows that it does not.”

Wherry and his collaborators used PD-1 knockout mice infected with lymphocytic choriomeningitis virus to see whether the genetic deletion of PD-1 would be enough to prevent T cell exhaustion. They observed a robust initial T cell response, but with a cost.

“While transient disruption of this pathway may have therapeutic benefit because it temporarily revs up the immune response, permanent loss of PD-1 signals seems to result in a flame out where T cells can't sustain higher level activation and become more dysfunctional,” Wherry said.

After a month or so, he explained, “the advantages in proliferation and other signaling pathways that cells had without PD-1 go away.”

Without the regulatory influence of PD-1, the overactivated and overstimulated T cells result in disruption of a crucial balance between different T cell types that leads to an overall greatly reduced immune response.

The work demonstrates that even with the clinical successes of blocking PD-1, there may be a better, more refined therapeutic strategy to target the PD-1 pathway.

“We know that transient blockade has tremendous benefit,” Wherry said. “But we also knew that there are subtypes of exhausted T cells that can or cannot be revitalized by transient PD-1 blockade. Our new work shows that PD-1 signals help regulate this balance.”

In effect, PD-1 may actually help to preserve a reserve force of T cells that can fight on later in the long-term cellular war between the immune system and foreign invaders or tumors.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs